Background-We retrospectively analyzed the potential of sirolimus as a primary immunosuppressant in the long-term attenuation of cardiac allograft vasculopathy progression and the effects on cardiac-related morbidity and mortality. Methods and Results-Forty-five cardiac transplant recipients were converted to sirolimus 1.2 years (0.2, 4.0) after transplantation with complete calcineurin inhibitor withdrawal. Fifty-eight control subjects 2.0 years (0.2, 6.5 years) from transplantation were maintained on calcineurin inhibitors. Age, sex, ejection fraction, and time from transplantation to baseline intravascular ultrasound study were not different (PϾ0.2 for all) between the groups; neither were secondary immunosuppressants and use of steroids. Three-dimensional intravascular ultrasound studies were performed at baseline and 3.1 years (1.3, 4.6 years) later. Plaque index progression (plaque volume/vessel volume) was attenuated in the sirolimus group (0.7Ϯ10.5% versus 9.3Ϯ10.8%; Pϭ0.0003) owing to reduced plaque volume in patients converted to sirolimus early (Ͻ2 years) after transplantation (Pϭ0.05) and improved positive vascular remodeling (Pϭ0.01) in patients analyzed late (Ͼ2 years) after transplantation. Outcome analysis in 160 consecutive patients maintained on 1 therapy was performed regardless of performance of intravascular ultrasound examinations. Five-year survival was improved with sirolimus (97.4Ϯ1.8% versus 81.8Ϯ4.9%; Pϭ0.006), as was freedom from cardiac-related events (93.6Ϯ3.2% versus 76.9Ϯ5.5%; Pϭ0.002).
C ardiac allograft vasculopathy (CAV) remains the leading cause of late morbidity and mortality in heart transplant recipients 1 and accounts for a third of all-cause mortality at 5 years. 2, 3 Immunosuppression after cardiac transplantation has traditionally comprised a calcineurin inhibitor (CNI) combined with mycophenolate mofetil or azathioprine and corticosteroids. This combination has improved short-term survival after heart transplantation but has not prevented the development of CAV. 4
Clinical Perspective on p 720
The typical approach to CAV has been modification of traditional risk factors and optimization of immunosuppres-sion. 5 Administration of lipid-lowering medications has been shown to slow but not prevent the development of CAV. 6 Sirolimus is a macrolide antibiotic with antiproliferative and potent antirejection properties. 7, 8 Sirolimus blocks proliferation of T and B cells by inhibiting their responses to growth factors, a different pathway than CNI. 7 In cardiac transplant recipients, sirolimus or its derivative, everolimus, has generally been used as a secondary immunosuppressive agent in place of azathioprine or mycophenolate mofetil. 9 -11 Our group has previously demonstrated attenuation of CAV with sirolimus-based immunosuppression over 1 year. 5, 12 Moreover, our data showed that a CNI-free regimen is safe and well tolerated and is most effective when initiated within the first 2 years after transplantation. 5, 12 From these initial observations, we hypothesized that replacement of CNI-based with sirolimus-based immunosuppression would be associated with less CAV progression and coronary vascular events (need for coronary intervention, myocardial infarction, graft failure related to CAV, and cardiac-related death) beyond the 12-month period. The aim of this study was therefore to investigate and compare the long-term efficacy of sirolimus and CNI as the primary immunosuppressant in preventing long-term CAV progression as assessed by serial 3-dimensional (3D) intravascular ultrasound (IVUS) examination and coronary angiography (using the recent nomenclature for CAV). 13 We also assessed the impact of primary sirolimus immunosuppression on the rate of coronary vascular events.
Methods

Study Design
This nonrandomized, retrospective, single-center study was approved by the Mayo Clinic institutional review board. The timing of the various measures and the design of the study are summarized in Figure 1 .
In the Mayo heart transplantation program, 3D IVUS has been performed since 2004 on most cardiac transplant recipients during routine annual coronary angiography as part of the surveillance for CAV. Until December 2008, a total of 90 cardiac transplant recipients were converted to sirolimus-based immunosuppression, as previously described. 12 The reasons for conversion to sirolimus have changed during the study period. Until July 2006, the reasons for conversion included impaired renal function secondary to CNI (glomerular filtration rate Յ50 mL/min and lack of any other identifiable causes of renal dysfunction) in 48 patients, CAV (any stenosis Ն50% in any major branch and/or distal pruning of secondary side branches) detected on annual coronary angiography in 6 patients, severe CNI-related side effects in 3 patients (1 with hirsutism and the other 2 with uncontrollable neuromuscular side effects), and conversion as a result of our newly introduced routine conversion protocol, in which we converted all patients interested in conversion 3 to 6 months after transplantation, in 4 patients. From July 2006 to December 2008, the reasons for conversion in the remaining 29 patients were renal dysfunction related to CNI in 3, CAV detected on annual angiography in 1, and our newly introduced routine conversion protocol in 25. Nineteen patients did not have a second IVUS examination; 15 patients were changed back from sirolimus-to CNI-based primary immunosuppression before a follow-up IVUS examination was performed (10 switched back to CNI before a planned surgery, 5 because of side effects [3 with sirolimusinduced lung injury, 2 with uncontrollable diarrhea]); 3 patients died before the second IVUS examination; and 8 patients re- Pϭ0.63). Some patients had Ͼ2 IVUS examinations performed, but only the differences between the first and the last IVUS data were analyzed. Nineteen patients in the sirolimus group did not have a second IVUS examination; 15 patients were changed back from sirolimus-to CNI-based primary immunosuppression before a follow-up IVUS examination was performed; 3 patients died before the second IVUS examination; and 8 patients remained on CNI concurrent with sirolimus and were excluded from the 3-dimensional (3D) IVUS analysis (but were included in the intention-to-treat outcome analysis). Four patients in the CNI group did not have a second IVUS examination; 8 patients died before the second IVUS examination and were excluded from the 3D IVUS analysis (but were included in the intention-to-treat outcome analysis). (C) Fifteen patients in the CNI group were converted after the second IVUS to sirolimus, and 8 of the sirolimus patients were converted back to CNI after completion of the second IVUS (dashed arrows). Analysis of outcome was performed in all 160 patients with at least 1 IVUS at baseline (90 patients on sirolimus, 70 patients on CNI) transplanted until December 2008, regardless of whether they were maintained on the same therapy (including patients who crossed over between therapies). Follow-up time started at the time of first IVUS extending beyond the time of the last IVUS up to the last clinical encounter with the patient (AϩBϩC). The last laboratory data were collected during the time of last IVUS.
mained on CNI concurrent with sirolimus. The remaining 45 patients who had undergone at least 2 consecutive 3D IVUS examinations on sirolimus as the primary immunosuppressant were included (sirolimus group) in the 3D IVUS analysis. Immunosuppression was transitioned from CNI to sirolimus 1.8 years (0.8, 4.0 years) after cardiac transplantation. Secondary immunosuppressive agents, mycophenolate mofetil or azathioprine, were left unchanged, as was the existing dose of prednisone.
A group of 70 cardiac transplantation patients who were maintained on standard primary immunosuppression with cyclosporin A (Gengraf, Abbott Laboratories, Abbott Park, IL; nϭ44) or tacrolimus (Prograf, Fujisawa Healthcare, Inc, Deerfield, IL; nϭ26) and had undergone at least 1 IVUS examination in the same time frame were identified (CNI group) and made up the control group for the outcome analysis. A group of 58 cardiac transplantation patients who had undergone at least 2 consecutive IVUS exams were selected from those 70 patients (36 on cyclosporin A and 22 on tacrolimus) and made up the control group for the IVUS analysis. Baseline characteristics for all patients (in both the sirolimus and CNI groups) were collected at the time of transplantation. All transplant recipients received induction therapy with low-dose OKT3 or ATG as part of a standard induction protocol. Cyclosporine A, tacrolimus, prednisone, azathioprine, and mycophenolate mofetil were managed and dosed as previously described. 5 Routine endomyocardial biopsies were performed weekly for 6 weeks after transplantation beginning a week after completion of the induction therapy, every 2 weeks from 6 weeks to 3 months, monthly from 3 to 6 months, and then at 3-month intervals until the end of the second year, as well as 10 to 15 days after any biopsy specimens that showed a rejection of grade 2R or higher.
Total rejection score was calculated for each patient before the first IVUS examination. Each biopsy result was graded and assigned a grading based on International Society for Heart and Lung Transplantation (ISHLT) R grading as 0Rϭ0, 1Rϭ1, 2Rϭ2, and 3Rϭ3. Total rejection score was calculated by dividing the cumulative scores for all the biopsies by the total number of biopsy specimens taken until the first IVUS examination in the individual patient. Any rejection score was calculated as 0Rϭ0, 1Rϭ1, 2Rϭ1, and 3Rϭ1 and represented the total number of rejections, regardless of severity, experienced by that patient during the same time period normalized for the total number of biopsy specimens.
Follow-Up and Clinical Outcomes
Exclusion of patients based on the presence or absence of a second IVUS examination may have resulted in bias in the outcome analysis. Inclusion of only the patients maintained on the same therapy also may result in selection bias because, by excluding patients who cross over to another therapy or need the addition of a second immunosuppressant, we may select only those who are doing better on their present therapy. To correct for these possible biases, survival and time to CAV-related adverse events were calculated from the time of first IVUS until the date of last clinical encounter in all 160 patients with at least 1 IVUS at baseline (90 patients on sirolimus, 58 patients on CNI with 2 IVUS examinations, and another 12 patients on CNI with 1 IVUS examination). Patients were censored at the time of their last follow-up. Patients were included in the sirolimus group if they survived the transplantation surgery, had at least 1 IVUS examination, and were converted to sirolimus anytime before that IVUS examination; patients were included in the CNI group if they survived the transplantation surgery, had at least 1 IVUS examination, and were maintained on CNI during the same time period, regardless of what happened next.
Clinical follow-up was obtained by review of medical records, surveys, and telephone interviews. The cause of death was determined by review of medical records and death certificates. Death related to CAV was defined as death resulting from myocardial infarction confirmed by pathological examination and/or an increase in cardiac-specific enzymes or abrupt death occurring in the setting of progressive CAV. Heart failure related to CAV was defined as readmission because of graft failure in a patient with known CAV and no other demonstrable cause of the clinical deterioration (no significant cellular rejection, no significant organic tricuspid regurgitation). The combined CAV-related outcome was defined as CAV-related mortality, myocardial infarction, or heart failure related to CAV or need for percutaneous intervention for CAV.
Coronary Angiography and IVUS Examination and Analysis
CAV was categorized with the use of the recent ISHLT guidelines. 13 Briefly, ISHLT CAV 0 (not significant) was defined as no detectable angiographic lesion; ISHLT CAV1 (mild) as angiographic left main Ͻ50%, primary vessel with a maximum lesion of Ͻ70%, or any branch stenosis Ͻ70% (including diffuse narrowing) without allograft dysfunction; ISHLT CAV2 (moderate) as angiographic left main Ͻ50%, a single primary vessel Ͼ70%, or isolated branch stenosis Ͼ70% in branches of 2 systems without allograft dysfunction; and ISHLT CAV3 (severe) as angiographic left main Ͼ50%, Ն2 primary vessels Ͼ70% stenosis, isolated branch stenosis Ͼ70% in all 3 systems, or ISHLT CAV1 or CAV2 with allograft dysfunction (defined as left ventricular ejection fraction Ͻ45% usually in the presence of regional wall motion abnormalities).
IVUS was performed at baseline (after conversion to sirolimus in the sirolimus group and at the time of inclusion in the study in the CNI group), with the last IVUS performed 3.1 years (1.3, 4.6 years) after the first IVUS. Fifty-seven patients had their first IVUS within the first 2 years after transplantation (early group). All the patients in the early group were converted to sirolimus Ͻ2 years after transplantation. In these patients, baseline IVUS examinations were performed 0.25 years (0.17, 1.04 years) after transplantation. The remaining 46 patients were examined 5.8 (4.0, 9.0 years) after transplantation (late group). All the patients in the late group were converted to sirolimus Ͼ2 years after transplantation.
The methods for conducting IVUS have been described elsewhere. 5, 14 Briefly, IVUS was performed during routine coronary angiography after intracoronary administration of 100 to 200 g nitroglycerin. Mechanical pullback (0.5 mm/s) was performed from the mid to distal left anterior descending coronary artery to the left main coronary artery with a 20-MHz, 2.9F, monorail, electronic Eagle Eye Gold IVUS imaging catheter (Volcano Therapeutics Inc, Rancho Cordova, CA) and a dedicated IVUS scanner (Volcano Therapeutics). The IVUS images were stored on a CD-ROM for later offline 3D volumetric IVUS analysis. Offline volumetric analysis of IVUS data was performed (Echo Plaque 2, version 2.5, INDECSystems Inc, Santa Clara, CA) by operators who were unaware of treatment assignment. The Simpson rule for volumetric measurement was used. Proximal and mid left anterior descending coronary artery regions were defined for the interrogated artery. Starting with the first complete vascular ring distal to the bifurcation with the left circumflex artery lumen, plaque volume (PV) and vessel volume (VV) were analyzed. Each measured volume was normalized to the examined segment length (mm 3 /mm) to compensate for differences in examined vessel segment length. A plaque index (PI) was calculated as follows: PIϭ(PV/VV)ϫ100%. An example of an IVUS study defining each of the measurements is shown in Figure 2 .
Changes in PV, lumen volume, and VV or PI were defined as absolute change in mm 3 calculated as last follow-up minus baseline volume measures value and as percent change. The semiautomated contour detection of both the lumen and media-adventitia interface was performed at intervals of either 16 or 32 frames, depending on the heterogeneity of the image. All other measurements were carried out automatically. Border detection was corrected manually in all frames after automatic border detection.
Statistical Analysis
Continuous normally distributed parameters were presented as meanϮSD and compared by use of the Student t test. Ordinal and/or nonnormally distributed variables were presented by median and first and third quartiles and compared by use of the nonparametric Wilcoxon rank-sum test. Differences from baseline to the follow-up IVUS examinations within groups were compared by use of a paired t test. IVUS values at the end of follow-up between groups were compared by ANCOVA, with the baseline value of the term or the baseline value and the time between IVUS examinations included in the analysis as a covariable. Categorical data were compared between groups with the 2 or Fisher exact test when the expected value in one of the cells was Ͻ5. Serial IVUS measurements were analyzed with the repeated-measures linear model. Survival distributions and time to CAV-related adverse events were calculated from the time of first IVUS according to the Kaplan-Meier method and compared by means of the log-rank test in all 160 patients transplanted until December 2008 who had at least 1 IVUS examination, were maintained on CNI, or were converted to sirolimus until that examination, regardless of whether they were maintained on the same therapy or had a second IVUS examination. Patients were censored at the time of last follow-up.
Unadjusted Cox proportional hazard models were used to analyze the association of the use of sirolimus with mortality rates or the time to vascular cardiac events with calculation of hazard ratios and confidence intervals. Adjusted Cox proportional hazard models were used to assess the independent association of sirolimus use adjusted for recipient and donor age.
All P values were 2-sided, and values of Ͻ0.05 were considered to indicate statistical significance. All data were analyzed with the JMP System software version 8.0 (SAS Institute, Inc, Cary, NC) apart from the repeated measures linear model which was analyzed with the SPSS 15 System software (SPSS Inc, Chicago, IL). All authors participated in designing the study, collecting and analyzing data, and drafting and revising the manuscript. Table 1 shows the comparison of baseline demographic, clinical, and laboratory characteristics between patients treated with CNI or sirolimus of the entire cohort. Table I in the online-only Data Supplement shows the comparison of baseline demographic, clinical, and laboratory characteristics between patients treated with CNI or sirolimus divided into patients having the first IVUS and converted Ͻ2 years (early group) and Ͼ2 years (late) after transplantation.
Results
Patient Characteristics
For the entire cohort, total rejection and any rejection scores were higher in the sirolimus group at baseline. The patients in the sirolimus group had a lower prevalence of congenital heart disease as their baseline diagnosis, but there was no difference in the prevalence of ischemic cardiomyopathy. There were no differences between the CNI and sirolimus groups in the entire cohort in terms of recipient age, sex, cytomegalovirus infection, donor age, conventional atherosclerosis risk factors, medical therapy, and secondary immunosuppression. Fifteen patients in the CNI group were converted to sirolimus 9.0 years (4.2, 11.5 years) after transplantation, all of them after the second IVUS examination. The reasons for late conversion to sirolimus in the CNI group were routine late conversion in 9 patients, conversion resulting from renal deterioration in 4 patients, conversion owing to accelerated CAV in 1 patient, and conversion resulting from CNI-related seizures in 1 patient. Eight of the sirolimus patients were converted back to CNI (9.0 years [4.4, 12.6 years] after transplantation) after the second IVUS examination. The reasons to go back on CNI were uncontrolled diabetes mellitus and hyperlipidemia in 3 patients, conversion before a planned surgery in 3 patients, severe mouth sores in 1 patient, and the need to add CNI to sirolimus because of chronic rejection in 1 patient. The time to change in immunosuppression from the transplantation was similar between the groups (Pϭ0.7).
Volumetric Changes in the Sirolimus and CNI Groups
Volumetric data by 3D IVUS at baseline and 3.1 years (1.3, 4.6 years) are shown in Table 2 . At baseline, 3D IVUS showed no difference in left anterior descending VV normalized per vessel length (VV/SL in mm 2 /mm), vessel lumen normalized per vessel length (LV/SL in mm 2 /mm), PV , which was interrogated for each examination, was measured (A). The semiautomated contour software detected both the bloodmedia interface defined as lumen area (LA) and the mediaadventitia interface defined as vessel area (VA). Plaque area (PA) was defined as the difference between VA and LA for each 2-dimensional image (B). Border detection was corrected manually in all frames after automatic border detection. Two-dimensional interrogations were performed at intervals of either 16 or 32 frames, depending on the heterogeneity of the image (C). Next, the vessel volume (VV), lumen volume (LV), and plaque volume (PV; mm 3 ) were calculated with the Simpson rule for volumetric measurement and corrected for the segment length (mm 3 /mm). Plaque index (PI) was calculated as follows: PIϭ(PV/VV)ϫ100%. CAV indicates cardiac allograft vasculopathy; SRL, sirolimus.
normalized per vessel length (PV/SL (in m 2 /mm), or ratio of PV to VV (PI in %) between the sirolimus and CNI groups.
VV/SL increased in both groups, suggestive of positive volumetric remodeling of the vessels as been described by others. 15, 16 The mean progression in PV was smaller in the sirolimus group than in the CNI group. The percent change in PV/SL was 37.0Ϯ66.8% in the sirolimus group versus 68.6Ϯ92.8% in the CNI group (Pϭ0.06). The combined effect of these processes resulted in no change in the lumen volume in the CNI group but significant dilatation of the luminal vessel in the sirolimus group. The progression in PI was significantly slower in the sirolimus group. In fact, the PI barely changed in the sirolimus-treated patients during an average follow-up period of Ͼ3 years. The total change was 0.7Ϯ10.5% in the sirolimus group compared with 9.4Ϯ10.8% in the CNI group (Pϭ0.0003). As assessed by PI, 34.1% of the sirolimus group and only 14.6% of the CNI group showed no disease progression (Pϭ0.02).
We have performed another analysis using the length of follow-up (time between IVUS examinations) as a second covariable in addition to the baseline value to adjust for the effect of length of follow-up on the volumetric changes in both groups. The use of sirolimus continued to significantly attenuate the progression of PV, PI, and change in lumen volume (PϽ0.05 for all). On the other hand, the impact of sirolimus on the progression of VV became nonsignificant when modifying for the effect of length of follow-up (Pϭ0.4). Effect interaction of treatment and time between IVUS examinations was checked with the use of an interaction term and multivariable analyses for PV progression, VV progression, lumen volume progression, and PI progression. There were no significant interactions between time between IVUS examinations and treatment (PϾ0.5 for all analyses). There was no association between changes in PV and PI and baseline creatinine (Pϭ0.96 and Pϭ0.70, respectively), glomerular filtration rate (Pϭ0.73 and Pϭ0.20, respectively), uric acid level (Pϭ0.78 and Pϭ0.78, respectively), and low-density lipoprotein cholesterol (Pϭ0.99 and Pϭ0.12, respectively) in univariable analysis.
Of note, the late group had a longer time period between the baseline and last IVUS examinations compared with the early group (4.1 years [2.3, 4.9 years] versus 1.9 years [1.0, 4.0 years]; Pϭ0.0002). Other differences between the groups were that in the late group the patients were younger; had a higher percent of patients transplanted for congenital heart disease, higher body mass index, higher triglyceride level, higher prevalence of hypertension, and higher use of calcium blockers and statins; and had a lower use of mycophenolate mofetil.
A comparison between CNI and sirolimus subdivided to the early and late groups revealed that the time period between IVUS examinations was similar between the CNI and sirolimus groups in both the early and late groups. Otherwise, the early group was similar to the total cohort, and the CNI and sirolimus groups differed only in the rejection scores (higher in sirolimus) and percent of ischemic cardiomyopathy (also higher in sirolimus). In the late group, on the other hand, there were some other differences between the sirolimus and CNI patients, with lower time to first IVUS, higher uric acid levels, lower glomerular filtration rate, and lower use of calcium blockers in the sirolimus patients. Otherwise, the sirolimus and CNI groups were comparable at baseline within these 2 subsets.
In patients observed in the first 2 years (early) after transplantation (0.9 years [0.17, 1.05 years] for the sirolimus group and 0.2 years [0.16, 1.02 years] for the CNI group; Pϭ0.53), the change in PV was smaller in the sirolimus group ( Figure 3A) and VV was increased in both groups ( Figure 3B) , resulting in increased PI in the CNI group compared with the sirolimus group ( Figure 3C ). In patients observed beyond the first 2 years (late) after transplantation (5.0 years [2.9, 7.0 years] for the sirolimus group and 6.5 years [4.3, 10.8 years] for the CNI group; Pϭ0.04), the change in PV was similar between groups ( Figure 3D) , but VV increased more in the sirolimus group ( Figure 3E) , resulting again in more progression of PI in the CNI group compared with the sirolimus group ( Figure 3F) . Table 3 compares laboratory parameters, total rejection score, any rejection score, and angiographically estimated CAV (categorized with the ISHLT guidelines) between the CNI and sirolimus groups at the end of follow-up in the entire cohort and divided into the early and late groups. The only differences in laboratory parameters at the end of follow-up between groups were a higher low-density lipoprotein cholesterol in the sirolimus group and a higher uric acid level in the CNI group. Although baseline CAV severity was similar between groups, the patients treated with sirolimus had significantly less deterioration in CAV (as assessed with the ISHLT nomenclature).
Serial Changes in Plaque and VV
Complete annual IVUS examinations for at least 3 years starting up to 3 months after transplantation were available in 28 transplant recipients (22 men; mean age, 54.3Ϯ11.4 years; 16 in the CNI and 12 in the sirolimus group). The first IVUS examinations were performed 7.8Ϯ2.8 weeks after transplantation. Table II in the online-only Data Supplement shows the comparison of baseline demographic, clinical, and laboratory characteristics between patients treated with CNI or sirolimus of those 28 patients.
During the first 3 years after heart transplantation, the average PV/length increased from 4.3Ϯ2.1 mm 3 /mm at baseline to 5.2Ϯ2.6 mm 3 /mm at year 1 to 6.2Ϯ4.1 mm 3 /mm at year 2 and to 7.5Ϯ4.3 mm 3 /mm in the CNI group but not in the sirolimus group ( Figure 4A) . The time course of VV changes is shown in Figure 4B . In the first year after heart transplantation, the average VV did not change in both groups. However, between years 1 and 3, VV expanded from 16.2Ϯ7.4 to 20.2Ϯ9.0 mm 3 /mm in the CNI group and from 13.9Ϯ4.5 to 16.5Ϯ4.7 mm 3 /mm in the sirolimus group. The increase in VV seemed to be delayed by a year in the sirolimus compared with the CNI group.
Vascular Events and Clinical Outcome
Survival and time to CAV-related adverse events were calculated from the time of first IVUS until the date of last clinical encounter in all 160 patients with at least 1 IVUS at baseline (90 patients on sirolimus, 70 patients on CNI) transplanted until December 2008. Patients were included in the sirolimus group if they survived the transplant surgery, had at least 1 IVUS examination, and were converted to sirolimus anytime before that IVUS examination. Patients were included in the CNI group if they survived the transplant surgery, had at least 1 IVUS examination, and were maintained on CNI during the same time period, regardless of what happened next. Table 4 shows the baseline demographic, clinical, and laboratory characteristics in those 160 patients comparing between patients treated with CNI and those treated with sirolimus. The only differences in baseline characteristics between the groups were that patients on sirolimus were older and had a shorter time period between transplantation and the first 3D IVUS examination.
Eighteen of the 160 patients (11.2%) died during followup, 13 (18.6%) in the CNI group versus 5 (5.6%) in the sirolimus group; 6 deaths (3 in each group) were related to severe coronary disease (3 with confirmed myocardial infarction on pathological examination, 1 died of cardiogenic shock after a failed coronary intervention, and 2 died suddenly and had known severe CAV). Five-year survival was improved with sirolimus (97.4Ϯ1.8% versus 81.8Ϯ4.9%; Pϭ0.006), as was the incidence of all-cause mortality (5.6% versus 18.6%; Pϭ0.01).
Eleven patients, 8 (11.4%) in the CNI group and 3 (3.3%) in the sirolimus group, required readmission because of graft failure related to severe CAV; 2 patients (all in the CNI group) had a myocardial infarction; and 7 patients, 5 (7.1%) in the CNI group and 2 (2.2%) in the sirolimus group, underwent percutaneous interventions for CAV. Twenty-six patients (16.2%) had at least 1 CAV-related event during follow-up (CAV-related mortality, myocardial infarction or heart failure related to CAV, or need for percutaneous intervention for CAV). The use of sirolimus resulted in a lower 5-year event rate (93.6Ϯ3.2% versus 76.9Ϯ5.5%; Pϭ0.002) and incidence of the combined CAV outcome (8.9% versus 25.7%; Pϭ0.004).
The time from transplantation to first IVUS was longer in the CNI group than in the sirolimus group (1.8 years [0.18, 5.6 years] versus 1.0 years [0.18, 2.9 years]; Pϭ0.04), and the recipient age was younger in the CNI group (29.1Ϯ28.7 years versus 38.5Ϯ24.9 years; Pϭ0.03).
The use of sirolimus reduced the rate of all-cause mortality and CAV-related events in univariable analysis and analysis adjusted for recipient age and time from transplantation to first IVUS examination (PϽ0.02 for all analyses; Table 5 ). Kaplan-Meier survival curves ( Figure 5) show considerable A, B , and C indicate changes in plaque volume, vessel volume, and plaque index between the first and last IVUS, respectively. Note that there is no difference in the change in vessel volume (VV) in the early group between patients treated with sirolimus (SRL) or calcineurin inhibitor (CNI) but that there is a delay in the progression of plaque volume (PV), resulting in a significant delay in the progression of plaque index (PI). On the other hand, in patients who were converted to sirolimus Ͼ2 years after transplantation, there is no difference in the rate of progression of plaque volume, but vessel volume increased more in the sirolimus-treated patients, resulting in a significantly decreased plaque index as well.
difference in the rate of CAV-related adverse outcomes in favor of sirolimus (Pϭ0.002).
Discussion
This is the first long-term (Ͼ1 year) comparable serial 3D IVUS and outcome study that demonstrates the use of sirolimus as a primary immunosuppressive agent for delaying the progression of CAV and lumen loss. The mechanism of mitigation of lumen loss changes with time after transplantation. In the initial years, it is by reducing the rate of intimal hyperplasia and plaque progression. Subsequently, it seems to be by delaying the characteristic biphasic response, consisting of early expansion and late constriction of VV (external elastic membrane). 15, 16 Our findings suggest that a CNI-free regimen is not only safe and well tolerated but also effective in decreasing CAV-related adverse outcomes and all-cause mortality.
Effects of Sirolimus on CAV
Currently, 3D IVUS is considered the gold standard for the evaluation of CAV 5, 16, 17 and quantifies both intimal thickening and changes in external elastic membrane area (arterial remodeling). This is an advantage in that several studies have emphasized that lumen loss in transplantation CAV is caused not only by intimal thickening but also by changes in external elastic membrane area. 15, 16, 18 Although randomized clinical trials have evaluated the role of sirolimus or its derivative, everolimus, in combination with cyclosporine for the prevention of CAV, 9, 10 there is paucity of data regarding the effect of complete CNI withdrawal and replacement with sirolimus on long-term progression of CAV and its clinical consequences. The use of combined sirolimus and CNI increases the risk of renal dysfunction as a result of the potentiation of the toxic effects of CNI, 9, 10 limiting the use of this combination in clinical practice.
Sirolimus attenuates endothelial cell proliferation and arterial smooth muscle cell proliferation and migration induced by platelet-derived growth factor and basic fibroblast growth factor. 19, 20 In contrast, CNI stimulate fibrogenic growth factor and transforming growth factor-␤ production, which may contribute to vasculopathy. 21 It is possible that the same signals perpetuating intimal proliferation initiate a cascade of pathways that adversely affect the ability of the coronary vessel to positively remodel. Although intimal thickening traditionally has been the focus of research, several observations indicate that impaired positive remodeling also contributes to a net lumen loss. 15, 16, 22 Our study showed no difference in VV between sirolimusand CNI-treated patients in the first year despite significantly higher plaque burden in the CNI group. This was followed by Table 3 mitigation of the characteristic biphasic response, consisting of early expansion and late constriction of VV (external elastic membrane). 15, 16 In patients treated with sirolimus, we observed a late positive remodeling on the vessel area contrasting with the late constriction observed in patients on CNI therapy. This suggests that the mechanism of slower progression of CAV with sirolimus involves an early phase (0 -3 years after transplantation) of reduced rate of intimal hyperplasia and plaque progression. Subsequently, the benefit appears to occur by delaying the characteristic late constriction of VV (external elastic membrane) distinctive of the process of CAV in patients treated with CNI. It is important to note that the impact of sirolimus on the progression of VV became nonsignificant when modifying for the effect of length of follow-up, suggesting that the differences between the groups in terms of VV may have been mediated at least in part by the time between IVUS examinations.
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We have recently shown that recurrent cellular rejection (assessed by the total rejection score and the any rejection score) has a cumulative effect on the onset of CAV. 23, 24 The mechanism may be due to the effect of endothelial progenitor cells that contribute to both rejection and CAV by being intrinsically involved in the rejection process and causing neointimal hyperplasia. 25 Cardiac transplant recipients with allograft vasculopathy have been observed to have a reduc- In other words, early rapid increase in plaque volume was observed in the CNI group, but plaque volume was stable in the sirolimus group up to 3 years after transplantation. Bottom, In the first year after heart transplantation, the average vessel volume did not change in both groups. However, between years 1 and 3, the vessel volume expanded in the CNI group. This expansion was delayed to the second year in the sirolimus group. In other words, after no significant change within the first year, serial changes in the vessel volume showed early expansion (between years 1 and 3) in the CNI group and a delayed expansion in the sirolimus group. The within-subject effect for plaque volume over time was significant (Pϭ0.003), but neither the between-subject effect (Pϭ0.4) nor the interaction of group with time (Pϭ0.3) was significant. The results of the analysis for vessel volume were nonsignificant for the within-subject effect, between-subject effect, and the interaction of group with time (PϾ0.2 for all), possibly as a result of the very small number of patients. tion in circulating endothelial cell precursors and seeding of these recipient-derived cells at the site of vasculopathy development. 25 A more recent study also demonstrated a reduction in circulating endothelial progenitor cells associated with decreased coronary flow reserve, suggesting involvement in CAV at the microvascular level. 26 These studies suggest that endothelial progenitor cells are active in the development of CAV at the site of initial vascular injury. In the present study, the rejection scores did not seem to be of much relevance in the face of sirolimus therapy. It is possible that the attenuation of the CAV in the context of recurrent cellular rejection by sirolimus may be through their potent cytotoxic effect on endothelial progenitor cells. 27 Converting to sirolimus therapy may reduce endothelial progenitor cell function and provide a novel mechanism to prevent rejection and possibly attenuate the development of CAV. Sirolimus also preferentially preserves the number and function of CD4 ϩ CD25 ϩ Foxp3 T lymphocytes (Tregs) compared with other T-cell subsets, unlike cyclosporine. 28 This has been demonstrated recently in mouse models of acute graft versus host disease in which the preservation of Tregs and resultant high Foxp3 expression probably attenuate T-cell-mediated cytotoxicity. 29 This indicates a new possible dimension of the mechanism of PV attenuation by sirolimus that could be related to enhanced Treg function and the facilitation of allograft tolerance by the recipient. We suggest that whatever immunological mechanisms may promote CAV development, the ability of sirolimus to switch off the proliferative response compensates for the immune-mediated damage.
Pathophysiology of Vessel Remodeling
We observed an increase in VV in the later years of follow-up in both the CNI and sirolimus groups. This finding is in accordance with previous reports. 16, 18 Currently, there is only limited knowledge about the pathophysiological mechanisms underlying coronary artery remodeling processes in transplantation patients. The response may be similar to the compensatory positive remodeling in early atherosclerosis of native coronary arteries as initially described by Glagov et al, 17 who postulated that an increase in shear forces induced by the augmented PV (such as seen in the first year after transplantation) may stimulate for dilation of the vascular wall, resulting in compensatory vessel enlargement. The attenuation in plaque progression in the first years in the sirolimus group may form the basis for the delayed positive vessel remodeling observed in this group. Another possible mechanism for vessel dilatation in transplantation patients may be a response to the intense inflammatory stimuli. Inflammatory cells likely play a major role in positive remodeling because of their production of metalloproteinases. 30 However, other inflammatory stimuli such as platelet-derived growth factor-induced connective tissue hyper- plasia and collagen synthesis 31-33 may be responsible for the opposite process of vessel constriction observed Ͼ3 years after heart transplantation. 16 In that respect, it is important to note that sirolimus is a powerful inhibitor of platelet-derived growth factor-induced proliferation 32 and collagen synthesis, 33 delaying constriction on one hand, but it enhances the expression of interstitial metalloproteinases, accelerating positive remodeling on the other. 34
Effects of Sirolimus as Primary Immunosuppression on CAV-Related Clinical Outcome
The results of our study confirm that primary immunosuppression with sirolimus not only mitigates the progression of CAV evaluated by coronary angiography or 3D IVUS but also may have a positive clinical effect by reducing CAVrelated outcomes. The reduction in overall mortality, CAVrelated graft failure, and the combined CAV outcome was significant even when we studied all patients converted to sirolimus before the first IVUS, regardless of performance of a second IVUS examination or maintenance on the same therapy in an "intention-to-treat-like " analysis. The dramatically improved survival seen in the sirolimus group was related mostly to the significant decrease in cardiac-related mortality. This decrease, in turn, is most probably related to the attenuation in PV and PI progression, resulting in increased coronary lumen, better coronary perfusion, less ischemic injury, and possibly improved long-term cardiac systolic and diastolic function. Another possible explanation may be that the potent antiinflammatory effects and heightened production of nitric oxide with sirolimus 9 may stabilize plaque and result in fewer acute coronary events, beyond what is expected by the attenuation in lumen loss.
Interestingly, we also observed a trend for a reduced incidence of cancer in the sirolimus group. These differences did not reach statistical significance (Pϭ0.15) but are intriguing in the context of the known antiproliferative properties of sirolimus. 19, 32, 33 It is important to stress that because of the lack of randomization, small number of events, and retrospective nature of our analysis, the differences in survival should be interpreted cautiously and that prospective clinical trials are required to prove whether sirolimus indeed improves longterm survival in heart transplant patients.
Recent studies comparing the outcome in heart transplant recipients on de novo sirolimus immunosuppression regimen started immediately after transplantation have shown that the incidence of surgical wound complications and symptomatic pleural and large pericardial effusions requiring intervention is significantly higher with de novo sirolimus. 35, 36 We and others have shown that early conversion to sirolimus is safe in that respect as long as it is performed 3 to 6 months after transplantation. 5, 37 
Conversion to Sirolimus
In light of the finding of this study and our previous work, 5 we have changed our routine immunosuppression since July 2006. Instead of conversion to sirolimus only in patients with impaired renal function secondary to CNI, accelerated CAV, or severe CNI-related side effects, transition to sirolimus transition is performed routinely in most patients between 3 and 6 months after transplantation, assuming a normal biopsy before conversion and the patient's desire. CNI doses are reduced first (cyclosporine dose reduced by 25 mg twice a day and tacrolimus dose reduced by 1 mg twice a day), and sirolimus is started at 1 mg/d. Sirolimus levels are checked every 10 days and adjusted accordingly. Once sirolimus target levels are achieved (8 -14 ng/mL), CNI is withdrawn and a biopsy is repeated 2 weeks later. If biopsies are positive for rejection, CNI is reintroduced at a reduced dose (aiming at 50% of previous levels). CNI withdrawal is attempted again once rejection subsided. If sirolimus withdrawal is needed (ie, planned surgery), it should be completed 4 to 6 weeks before anticipated surgery if feasible. We restart CNI at previous stable dosages, and once the level is adequate, we stop sirolimus.
Study Limitations
Conversion from a CNI-based regimen to sirolimus was changed during the study period from conversion in patients with impaired renal function secondary to CNI, CAV detected on annual coronary angiography, or uncontrollable CNI-related side effects to routine conversion in all patients interested in conversion 3 to 6 months after transplantation. The lack of randomized conversion is a source of bias in our study. The loss of half of the original patients who were converted to sirolimus for numerous reasons and especially those who died before having a second IVUS examination or were converted back to CNI as a result of side effects may have biased our IVUS results in favor of the sirolimus group. We acknowledge that even after the "intention-to-treat-like" analysis the results may still be biased by baseline differences between the groups. The patients in the CNI group were later in their posttransplantation course compared with the sirolimus group. It is possible that the longer follow-up in the CNI group may have included patients with more established coronary lesions because there is a close relationship between plaque progression and number of years after transplantation. The patients in the late group differed from the patients in the early group in several parameters, which may have been a source of bias in the IVUS subgroup analysis.
Conclusions
Sirolimus not only is effective as a primary immunosuppressant compared with CNIs but also has long-term properties that mitigate CAV progression by reducing intimal hyperplasia and may improve the impaired positive remodeling characteristic of CAV in patients on primary CNI immunosuppression. Furthermore, the geometric vascular changes seem to be translated to improved survival and fewer CAVrelated adverse outcomes. These beneficial effects are more pronounced if conversion to sirolimus takes place within the first 2 years after transplantation but seem to persist even in later phases. Our findings suggest that early conversion to sirolimus should be considered for primary immunosuppressive therapy after cardiac transplantation. This strategy may have the potential to prevent or retard the development of CAV and to improve long-term survival after cardiac allotransplantation. Because of the small numbers, the lack of randomization of therapy, and the retrospective nature of our analysis, the differences in outcome should be interpreted cautiously, and prospective clinical trials are required to recommend sirolimus as a primary immunosuppressant.
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